Plasma Prostaglandin E2 Metabolite Levels Predict Type 2 Diabetes Status and One-Year Therapeutic Response Independent of Clinical Markers of Inflammation

Over half of patients with type 2 diabetes (T2D) are unable to achieve blood glucose targets despite therapeutic compliance, significantly increasing their risk of long-term complications. Discovering ways to identify and properly treat these individuals is a critical problem in the field. The arachidonic acid metabolite, prostaglandin E2 (PGE2), has shown great promise as a biomarker of β-cell dysfunction in T2D. PGE2 synthesis, secretion, and downstream signaling are all upregulated in pancreatic islets isolated from T2D mice and human organ donors. In these islets, preventing β-cell PGE2 signaling via a prostaglandin EP3 receptor antagonist significantly improves their glucose-stimulated and hormone-potentiated insulin secretion response. In this clinical cohort study, 167 participants, 35 non-diabetic, and 132 with T2D, were recruited from the University of Wisconsin Hospital and Clinics. At enrollment, a standard set of demographic, biometric, and clinical measurements were performed to quantify obesity status and glucose control. C reactive protein was measured to exclude acute inflammation/illness, and white cell count (WBC), erythrocyte sedimentation rate (ESR), and fasting triglycerides were used as markers of systemic inflammation. Finally, a plasma sample for research was used to determine circulating PGE2 metabolite (PGEM) levels. At baseline, PGEM levels were not correlated with WBC and triglycerides, only weakly correlated with ESR, and were the strongest predictor of T2D disease status. One year after enrollment, blood glucose management was assessed by chart review, with a clinically-relevant change in hemoglobin A1c (HbA1c) defined as ≥0.5%. PGEM levels were strongly predictive of therapeutic response, independent of age, obesity, glucose control, and systemic inflammation at enrollment. Our results provide strong support for future research in this area.

[1]  F. Ginhoux,et al.  Role of adipose tissue macrophages in obesity-related disorders , 2022, The Journal of experimental medicine.

[2]  M. Gannon,et al.  Effects of Arachidonic Acid and Its Metabolites on Functional Beta-Cell Mass , 2022, Metabolites.

[3]  B. Berthon,et al.  Weight Loss and Short-Chain Fatty Acids Reduce Systemic Inflammation in Monocytes and Adipose Tissue Macrophages from Obese Subjects , 2022, Nutrients.

[4]  R. Kukreti,et al.  Mechanistic Insight into Oxidative Stress-Triggered Signaling Pathways and Type 2 Diabetes , 2022, Molecules.

[5]  R. Breyer,et al.  Pharmacological blockade of the EP3 prostaglandin E2 receptor in the setting of type 2 diabetes enhances β-cell proliferation and identity and relieves oxidative damage , 2021, Molecular metabolism.

[6]  D. Davis,et al.  Human Islet Expression Levels of Prostaglandin E2 Synthetic Enzymes, But Not Prostaglandin EP3 Receptor, Are Positively Correlated with Markers of β-Cell Function and Mass in Nondiabetic Obesity. , 2021, ACS Pharmacology & Translational Science.

[7]  Ling Geng,et al.  Comparison of the triglyceride glucose index and blood leukocyte indices as predictors of metabolic syndrome in healthy Chinese population , 2021, Scientific Reports.

[8]  Yongman Lv,et al.  The role of systemic inflammation in the association between serum 25-hydroxyvitamin D and type 2 diabetes mellitus. , 2021, Clinical nutrition.

[9]  R. Breyer,et al.  Rat prostaglandin EP3 receptor is highly promiscuous and is the sole prostanoid receptor family member that regulates INS‐1 (832/3) cell glucose‐stimulated insulin secretion , 2021, Pharmacology research & perspectives.

[10]  Dudley Lamming,et al.  Systemic Metabolic Alterations Correlate with Islet-Level Prostaglandin E2 Production and Signaling Mechanisms That Predict β-Cell Dysfunction in a Mouse Model of Type 2 Diabetes , 2021, Metabolites.

[11]  Kathryn A Carbajal,et al.  Agonist-independent Gαz activity negatively regulates beta-cell compensation in a diet-induced obesity model of type 2 diabetes , 2020, The Journal of biological chemistry.

[12]  A. Barsch,et al.  Ultrahigh-Resolution Mass Spectrometry-Based Platform for Plasma Metabolomics Applied to Type 2 Diabetes Research. , 2020, Journal of proteome research.

[13]  J. Wan,et al.  Quantitative profiling of eicosanoids derived from n-6 and n-3 polyunsaturated fatty acids by twin derivatization strategy combined with LC-MS/MS in patients with type 2 diabetes mellitus. , 2020, Analytica chimica acta.

[14]  R. Wevers,et al.  Evaluation of cyclooxygenase oxylipins as potential biomarker for obesity-associated adipose tissue inflammation and type 2 diabetes using targeted multiple reaction monitoring mass spectrometry. , 2020, Prostaglandins, leukotrienes, and essential fatty acids.

[15]  Minjoo Kim,et al.  Inflammatory Markers and Plasma Fatty Acids in Predicting WBC Level Alterations in Association With Glucose-Related Markers: A Cross-Sectional Study , 2020, Frontiers in Immunology.

[16]  A. Sikalidis,et al.  The Gut Microbiome and Type 2 Diabetes Mellitus: Discussing A Complex Relationship , 2020, Biomedicines.

[17]  A. Das,et al.  Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D). , 2019, The Journal of the Association of Physicians of India.

[18]  X. Hou,et al.  Serum Metrnl Level is Correlated with Insulin Resistance, But Not with β-Cell Function in Type 2 Diabetics , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[19]  B. Thorens,et al.  Use of preclinical models to identify markers of type 2 diabetes susceptibility and novel regulators of insulin secretion – A step towards precision medicine , 2019, Molecular metabolism.

[20]  P. Jakobsson,et al.  Urinary prostaglandin D2 and E2 metabolites associate with abdominal obesity, glucose metabolism, and triglycerides in obese subjects. , 2019, Prostaglandins & other lipid mediators.

[21]  G. Rogers,et al.  The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release , 2019, Front. Physiol..

[22]  D. Eizirik,et al.  Biomarkers of islet beta cell stress and death in type 1 diabetes , 2018, Diabetologia.

[23]  L. Groop,et al.  Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. , 2018, The lancet. Diabetes & endocrinology.

[24]  I. Harsch,et al.  The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into “Old” Diseases , 2018, Medical sciences.

[25]  J. Nessler,et al.  Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease , 2018, Cardiovascular Diabetology.

[26]  N. Inagaki,et al.  Regulation of glucagon‐like peptide‐1 sensitivity by gut microbiota dysbiosis , 2017, Journal of diabetes investigation.

[27]  K. Sung,et al.  Inflammation in the Prediction of Type 2 Diabetes and Hypertension in Healthy Adults. , 2017, Archives of medical research.

[28]  M. Kimple,et al.  The EP3 Receptor/Gz Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease , 2017, The AAPS Journal.

[29]  Kathryn A Carbajal,et al.  The Inhibitory G Protein &agr;-Subunit, G&agr;z, Promotes Type 1 Diabetes-Like Pathophysiology in NOD Mice , 2017, Endocrinology.

[30]  R. Robertson,et al.  The COX-2/PGE2/EP3/Gi/o/cAMP/GSIS Pathway in the Islet: The Beat Goes On , 2017, Diabetes.

[31]  Bethany A. Carboneau,et al.  Opposing effects of prostaglandin E2 receptors EP3 and EP4 on mouse and human β-cell survival and proliferation , 2017, Molecular metabolism.

[32]  K. Eliceiri,et al.  Enriching Islet Phospholipids With Eicosapentaenoic Acid Reduces Prostaglandin E2 Signaling and Enhances Diabetic β-Cell Function , 2017, Diabetes.

[33]  A. Owora Diagnostic Validity and Clinical Utility of HbA1C Tests for Type 2 Diabetes Mellitus , 2016, Current diabetes reviews.

[34]  R. Mirmira,et al.  Biomarkers of β-Cell Stress and Death in Type 1 Diabetes , 2016, Current Diabetes Reports.

[35]  A. Scheen Precision medicine: The future in diabetes care? , 2016, Diabetes research and clinical practice.

[36]  M. Kimple,et al.  Dietary polyunsaturated fatty acids and their metabolites: Implications for diabetes pathophysiology, prevention, and treatment , 2016, Nutrition and healthy aging.

[37]  M. Kimple,et al.  Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes. , 2016, Molecular endocrinology.

[38]  Allan Vaag,et al.  Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes , 2016, Nature Communications.

[39]  Sher Ali,et al.  Genes, Genetics, and Environment in Type 2 Diabetes: Implication in Personalized Medicine. , 2016, DNA and cell biology.

[40]  2. Classification and Diagnosis of Diabetes , 2014, Diabetes Care.

[41]  G. Sesti,et al.  Unfavorable inflammatory profile in adults at risk of type 2 diabetes identified by hemoglobin A1c levels according to the American Diabetes Association criteria , 2015, Acta Diabetologica.

[42]  A. Piwowar,et al.  [Associations between basic indicators of inflammation and metabolic disturbances]. , 2014, Postepy higieny i medycyny doswiadczalnej.

[43]  D. Juárez,et al.  Failure to reach target glycated a1c levels among patients with diabetes who are adherent to their antidiabetic medication. , 2014, Population health management.

[44]  V. Mohan,et al.  Association of neutrophil-lymphocyte ratio with glucose intolerance: an indicator of systemic inflammation in patients with type 2 diabetes. , 2014, Diabetes technology & therapeutics.

[45]  P. Casey,et al.  Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes , 2014, Experimental & Molecular Medicine.

[46]  M. Nieuwdorp,et al.  Role of the microbiome in energy regulation and metabolism. , 2014, Gastroenterology.

[47]  F. Welty How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis? , 2013, Current Cardiology Reports.

[48]  M. Kimple,et al.  The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics. , 2013, Journal of endocrinology, diabetes & obesity.

[49]  A. Attie,et al.  Prostaglandin E2 Receptor, EP3, Is Induced in Diabetic Islets and Negatively Regulates Glucose- and Hormone-Stimulated Insulin Secretion , 2013, Diabetes.

[50]  M. Carnero,et al.  Relationship between serum levels of triglycerides and vascular inflammation, measured as COX-2, in arteries from diabetic patients: a translational study , 2013, Lipids in Health and Disease.

[51]  L. Makowski,et al.  The inflammation highway: metabolism accelerates inflammatory traffic in obesity , 2012, Immunological reviews.

[52]  R. Robertson,et al.  Cyclooxygenase-2, Not Microsomal Prostaglandin E Synthase-1, Is the Mechanism for Interleukin-1β-induced Prostaglandin E2 Production and Inhibition of Insulin Secretion in Pancreatic Islets* , 2012, The Journal of Biological Chemistry.

[53]  P. Casey,et al.  Deletion of GαZ Protein Protects against Diet-induced Glucose Intolerance via Expansion of β-Cell Mass* , 2012, The Journal of Biological Chemistry.

[54]  Shih-Yi Lin,et al.  Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies , 2010, PloS one.

[55]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[56]  A. Syrenicz,et al.  Low-grade systemic inflammation and the risk of type 2 diabetes in obese children and adolescents. , 2006, Neuro endocrinology letters.

[57]  P. Casey,et al.  A Role for Gz in Pancreatic Islet β-Cell Biology* , 2005, Journal of Biological Chemistry.

[58]  W. März,et al.  Low-Density Lipoprotein Triglycerides Associated With Low-Grade Systemic Inflammation, Adhesion Molecules, and Angiographic Coronary Artery Disease: The Ludwigshafen Risk and Cardiovascular Health Study , 2004, Circulation.

[59]  J. Vane,et al.  The mechanism of action of aspirin. , 2003, Thrombosis research.

[60]  R. Robertson,et al.  Inhibition of Interleukin-1β-Induced COX-2 and EP3 Gene Expression by Sodium Salicylate Enhances Pancreatic Islet β-Cell Function , 2002 .

[61]  Christian Weyer,et al.  High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. , 2002, Diabetes.

[62]  R. Robertson,et al.  Prostaglandin E2 Mediates Inhibition of Insulin Secretion by Interleukin-1β* , 1999, The Journal of Biological Chemistry.

[63]  R. Robertson,et al.  Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. , 1998, Diabetes.

[64]  Å. Sjöholm,et al.  Prostaglandins inhibit pancreatic beta-cell replication and long-term insulin secretion by pertussis toxin-insensitive mechanisms but do not mediate the actions of interleukin-1 beta. , 1996, Biochimica et biophysica acta.

[65]  S. Bonakdaran,et al.  Correlation Between White Blood Cell Count and Insulin Resistance in Type 2 Diabetes. , 2018, Current diabetes reviews.

[66]  BOULIN,et al.  Classification and Diagnosis of Diabetes. , 2022, Primary care.

[67]  T. Forst,et al.  A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus. , 2008, Clinical Laboratory.

[68]  J. Chan,et al.  White blood cell count is associated with macro- and microvascular complications in chinese patients with type 2 diabetes. , 2004, Diabetes care.